PL3386527T3 - Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny - Google Patents
Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migrenyInfo
- Publication number
- PL3386527T3 PL3386527T3 PL16873645T PL16873645T PL3386527T3 PL 3386527 T3 PL3386527 T3 PL 3386527T3 PL 16873645 T PL16873645 T PL 16873645T PL 16873645 T PL16873645 T PL 16873645T PL 3386527 T3 PL3386527 T3 PL 3386527T3
- Authority
- PL
- Poland
- Prior art keywords
- neurodegeneration
- migraine
- compositions
- treating
- neuropathic pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/99—Racemaces and epimerases (5.1) acting on other compounds (5.1.99)
- C12Y501/99006—NAD(P)H-hydrate epimerase (5.1.99.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562265752P | 2015-12-10 | 2015-12-10 | |
EP16873645.2A EP3386527B1 (en) | 2015-12-10 | 2016-12-05 | Compositions for use in treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
PCT/US2016/064938 WO2017100125A1 (en) | 2015-12-10 | 2016-12-05 | Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3386527T3 true PL3386527T3 (pl) | 2022-01-31 |
Family
ID=59013143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16873645T PL3386527T3 (pl) | 2015-12-10 | 2016-12-05 | Kompozycje do zastosowania w leczeniu lub łagodzeniu neurozapalenia, neurodegeneracji, bólu neuropatycznego i migreny |
Country Status (8)
Country | Link |
---|---|
US (2) | US10729788B2 (pl) |
EP (1) | EP3386527B1 (pl) |
DK (1) | DK3386527T3 (pl) |
ES (1) | ES2883417T3 (pl) |
HU (1) | HUE055326T2 (pl) |
PL (1) | PL3386527T3 (pl) |
PT (1) | PT3386527T (pl) |
WO (1) | WO2017100125A1 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112533642A (zh) * | 2018-05-17 | 2021-03-19 | 赫利世弥斯株式会社 | 治疗与化疗诱发的周围神经病变相关的神经性疼痛 |
US20230181686A1 (en) * | 2020-05-27 | 2023-06-15 | Baylor College Of Medicine | Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport |
WO2022081245A1 (en) * | 2020-10-13 | 2022-04-21 | The Methodist Hospital System | Compositions and methods for increasing lymphangiogenesis |
EP4308233A1 (en) * | 2021-03-18 | 2024-01-24 | The Regents of the University of California | Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8513702D0 (en) | 1985-05-30 | 1985-07-03 | Gill S S | Expansible trocar |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US7343205B1 (en) | 2002-08-20 | 2008-03-11 | Boston Scientific Neuromodulation Corp. | System and method for insertion of a device into the brain |
EP3067070A1 (en) | 2002-09-24 | 2016-09-14 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Method for convection enhanced delivery of therapeutic agents |
US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
WO2005063156A1 (en) | 2003-12-22 | 2005-07-14 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
EP1698329A4 (en) | 2003-12-24 | 2009-10-28 | Ltt Bio Pharma Co Ltd | PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
EP1773298A1 (en) | 2004-08-06 | 2007-04-18 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
WO2006044986A1 (en) | 2004-10-18 | 2006-04-27 | Nitto Denko Corporation | Intracellular peptide delivery |
US20060129126A1 (en) | 2004-11-19 | 2006-06-15 | Kaplitt Michael G | Infusion device and method for infusing material into the brain of a patient |
AU2006274413B2 (en) | 2005-07-27 | 2013-01-10 | Arbutus Biopharma Corporation | Systems and methods for manufacturing liposomes |
CN100357325C (zh) | 2005-10-23 | 2007-12-26 | 王贤理 | 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒 |
WO2008067183A1 (en) | 2006-11-30 | 2008-06-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | A device for cell delivery into the brain or body |
US20080140056A1 (en) | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Method for delivering large molecules to the brain |
WO2012019060A1 (en) | 2010-08-05 | 2012-02-09 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
US9283262B2 (en) | 2010-12-07 | 2016-03-15 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
US10364275B2 (en) | 2013-05-27 | 2019-07-30 | The Regents Of The University Of California | Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP) |
-
2016
- 2016-12-05 DK DK16873645.2T patent/DK3386527T3/da active
- 2016-12-05 HU HUE16873645A patent/HUE055326T2/hu unknown
- 2016-12-05 US US16/060,576 patent/US10729788B2/en active Active
- 2016-12-05 PT PT168736452T patent/PT3386527T/pt unknown
- 2016-12-05 WO PCT/US2016/064938 patent/WO2017100125A1/en unknown
- 2016-12-05 ES ES16873645T patent/ES2883417T3/es active Active
- 2016-12-05 PL PL16873645T patent/PL3386527T3/pl unknown
- 2016-12-05 EP EP16873645.2A patent/EP3386527B1/en active Active
-
2020
- 2020-06-23 US US16/909,896 patent/US11478556B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE055326T2 (hu) | 2021-11-29 |
US20180360993A1 (en) | 2018-12-20 |
US11478556B2 (en) | 2022-10-25 |
PT3386527T (pt) | 2021-09-27 |
ES2883417T3 (es) | 2021-12-07 |
US20200390906A1 (en) | 2020-12-17 |
EP3386527A4 (en) | 2019-07-03 |
DK3386527T3 (da) | 2021-08-23 |
EP3386527B1 (en) | 2021-05-26 |
EP3386527A1 (en) | 2018-10-17 |
US10729788B2 (en) | 2020-08-04 |
WO2017100125A1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL304820A (en) | Preparations and methods for the treatment of cancer | |
PT3377516T (pt) | Composição para o tratamento do cancro | |
HK1258696A1 (zh) | 治療或預防皮膚障礙的新型組合物和方法 | |
IL256523A (en) | Compositions and methods for treating cancer | |
IL269637A (en) | Preparations and methods for the treatment of synovial diseases | |
HK1258825A1 (zh) | 用於治療多汗症的方法和組合物 | |
HK1256541A1 (zh) | 用於處理皮膚的方法和組合物 | |
HK1258502A1 (zh) | 用於治療高胱氨酸尿症的組合物和方法 | |
HUE055326T2 (hu) | Készítmények ideggyulladás, neurodegeneráció, neuropátiás fájdalom és migrén kezelésében vagy enyhítésében történõ alkalmazásra | |
EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
IL255638A (en) | Compositions and methods for treating cancer | |
IL271923A (en) | Methods and compositions for treating addictions | |
IL269550A (en) | Preparations and methods for treating diseases related to alpha-synuclein | |
IL251881A0 (en) | Preparations for the treatment of acute, post-operative or chronic pain and methods of using them | |
HK1248130A1 (zh) | 用於治療疼痛的組合物 | |
IL274822A (en) | Substances for the treatment of depression and migraine | |
IL271758A (en) | Statin preparations and methods for use in the treatment of synuclein pathologies | |
IL271211B1 (en) | Acetyl leucine for use in the treatment of migraine | |
ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
IL272945A (en) | Local preparations and methods of treatment | |
HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
IL257407A (en) | Compositions and methods for treating wounds | |
GB201704759D0 (en) | Compounds and compositions for use in treating psoriasis | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
GB201508518D0 (en) | Hair treatment compositions and methods |